ストックスクリーナーアプリを入手
21.87
9.89%
-2.40
アフターアワーズ：
21.93
0.06
+0.27%
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
(APLS) Investment Analysis - news.stocktradersdaily.com
Fierce Biotech Layoff Tracker 2025: Elevation eliminates 70% of staff; ElevateBio trims team - Fierce Biotech
Is Apellis Pharmaceuticals, Inc. (APLS) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Apellis Pharma stock hits 52-week low at $23.77 amid market challenges - Investing.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Apellis Pharmaceuticals chief development officer sells shares worth $39,279 - MSN
Apellis Pharmaceuticals (APLS) Gets a Hold from Scotiabank - The Globe and Mail
Cardurion Taps Apellis Veteran Who Led 450% Team Growth for Top HR Role - StockTitan
University Retina Participate in Apellis Pharmaceuticals’ Groundbreaking Clinical Trials for SYFOVRE, the first and only FDA-approved treatment for Geographic Atrophy - Business Wire
Apellis Pharmaceuticals CFO Timothy Sullivan sells $51,827 in stock - MSN
(APLS) Long Term Investment Analysis - news.stocktradersdaily.com
Apellis Pharmaceuticals executive sells shares valued at $4,542 By Investing.com - Investing.com Australia
JP Morgan Cut Apellis' Price Forecasts, Cites Longer Peak Sales Timing For Syfovre - Benzinga
Apellis Pharmaceuticals Beats Investor Suit Over Eye Drug Risks - Bloomberg Law News
Apellis Pharmaceuticals executive sells shares valued at $4,542 - Investing.com India
Apellis Pharmaceuticals (NASDAQ:APLS) Is Making Moderate Use Of Debt - Simply Wall St
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Bank of New York Mellon Corp - Defense World
Victory Capital Management Inc. Purchases 150,363 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
Will Apellis Pharma's Empaveli Prove VALIANT In Battling Rare Kidney Diseases? - RTTNews
Learn to Evaluate (APLS) using the Charts - news.stocktradersdaily.com
Apellis Pharmaceuticals general counsel sells shares for $139,789 By Investing.com - Investing.com South Africa
Layoff Tracker: Atea Pharmaceuticals Cuts 25% of Workforce - BioSpace
Insider Sells Thousands of Apellis Pharmaceuticals Shares! - TipRanks
Apellis Pharmaceuticals general counsel sells shares for $139,789 - Investing.com India
Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics - MSN
HC Wainwright Issues Pessimistic Forecast for APLS Earnings - Defense World
Wedbush Lifts Earnings Estimates for Apellis Pharmaceuticals - Defense World
Apellis Lead Drug Pegcetacoplan Represents Differentiated Asset: JP Morgan Analyst - Benzinga
Wedbush Issues Optimistic Outlook for APLS Earnings - Defense World
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues - MSN
Apellis Pharmaceuticals: A Mixed Bag (NASDAQ:APLS) - Seeking Alpha
UBS Adjusts Apellis Pharmaceuticals Price Target to $43 From $45, Maintains Buy Rating - Marketscreener.com
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2024 Earnings Call Transcript - MSN
JPMorgan Chase & Co. Issues Positive Forecast for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - Defense World
Apellis Pharmaceuticals Faces Financial Challenges Amid Ambitious Drug Commercialization Efforts - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $29.00 by Analysts at Wedbush - Defense World
Apellis Pharmaceuticals’ (APLS) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $32.00 at The Goldman Sachs Group - Defense World
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $25.00 at Royal Bank of Canada - Defense World
Apellis Class Action: Levi & Korsinsky Reminds Apellis Pharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 2, 2023 – APLS - ACCESS Newswire
Breaking Down Apellis Pharmaceuticals: 6 Analysts Share Their Views - Benzinga
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Apellis Pharmaceuticals, Inc.(APLS) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
New York State Common Retirement Fund Sells 327,776 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) - Defense World
1.05%
1.79%
大文字化:
|
ボリューム (24 時間):